natgillin/translations-raw huggingface dataset:
Gently remove surgical gauze or laparotomy pads from the application site, without disrupting or dislodging EVARREST or the clot. 
Nežno odstranite kirurško gazo ali blazinice za laparotomijo z mesta namestitve, ne da bi pri tem premaknili ali odstranili zdravilo EVARREST ali strdek.
Human Fibrinogen: 
Izrael humani fibrinogen:
The bleeding source should be clearly identified, and it must be ensured that EVARREST is applied directly onto the bleeding source by covering it completely. 
Vir krvavitve je treba jasno določiti in zagotoviti, da je matriks zdravila EVARREST nameščen neposredno na viru krvavitve, tako da ga povsem prekriva.
The clot formation of EVARREST is integrated with the Matrix; it forms a mechanical barrier to bleeding and reinforces the wound site. 
Tvorba strdkov pri zdravilu EVARREST je lastnost matriksa; tvori mehansko pregrado do krvavitve in ojača mesto rane.
As with any product which is implanted, the body may develop a reaction to the foreign material. 
Kot pri vsakem vsadku tudi pri tem obstaja nevarnost za razvoj reakcije na tuji material.
Standard of Care was manual compression (MC) with or without a topical absorbable haemostat (TAH) or any other adjunctive haemostasis technique that was deemed by the surgeon to be his/her standard of care. 
Standardna oskrba je bila ročna kompresija ob uporabi topikalnega razgradljivega hemostatika ali brez nje oziroma ob uporabi katere koli druge dopolnilne hemostatske tehnike, ki jo je kirurg uvrščal v svojo standardno oskrbo.
MARKETING AUTHORISATION NUMBER(S) EU/1/13/868/001 
EU/1/13/868/001 EU/1/13/868/002
EVARREST must not be used to repair injuries to the wall of large arteries or veins where the product is exposed to constant blood flow and pressure. 
Zdravila EVARREST se ne sme uporabljati na poškodovanih stenah velikih arterij ali ven, kjer je zdravilo izpostavljeno nenehnemu krvnemu pretoku in tlaku.
Inspect EVARREST to verify that haemostasis has been achieved and to ensure that there is no crimping over the bleeding area. 
Preglejte zdravilo EVARREST in zagotovite, da je hemostaza dosežena in da se na mestu krvavitve matriks ni nagubal.
The dose to be applied is governed by variables including, but not limited to, the type of surgical intervention, the size of the area and the mode of intended application, and the number of applications. 
Odmerek za nanos je odvisen od več dejavnikov, med drugim od vrste kirurškega posega, velikosti območja in načina predvidene uporabe ter števila nanosov.
Two clinical studies in 206 patients undergoing hepatic surgery (110 treated with EVARREST and 96 with control) demonstrated haemostatic efficacy in persistent parenchymal bleeding. 
V dveh kliničnih študijah pri 206 bolnikih, ki so imeli kirurški poseg na jetrih (110 bolnikov je bilo zdravljenih z zdravilom EVARREST in 96 bolnikov je bilo zdravljenih s kontrolnim zdravilom), so dokazali hemostatsko učinkovitost pri vztrajni parenhimski krvavitvi.
EVARREST must not be stored above 25°C and must not be frozen. 
Zdravilo EVARREST shranjujte pri temperaturi do 25 °C in ga ne zamrzujte.
The composite Matrix is composed of polyglactin 910 and oxidized regenerated cellulose, a commonly used haemostat. 
Kompozitni matriks je sestavljen iz poliglaktina 910 in oksidirane regenerirane celuloze, ki se običajno uporablja kot hemostat.
The active side of the sealant matrix is powdery, and the non-active side has an embossed wave pattern. 
Aktivna stran matriksa je videti prahasta, na neaktivni strani pa je izbočen valovit vzorec.
A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALEC (IZDELOVALCI) BIOLOŠKE(IH) ZDRAVILNE(IH) UČINKOVINE (UČINKOVIN) IN IZDELOVALEC (IZDELOVALCI), ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ
Despite these measures, when medicines prepared from human blood or plasma are given, the possibility of passing on infection cannot be totally excluded. 
Vendar kljub tem ukrepom pri uporabi zdravil, pripravljenih iz človeške krvi ali plazme, ni mogoče povsem izključiti možnosti prenosa okužb.
EVARREST contains the components of fibrin sealant. 
Zdravilo EVARREST vsebuje komponente fibrinskega lepila.
EVARREST must not be used in closed spaces (for example, in, around, or next to openings or passages in the bone or other restricted areas around bone) where it could swell and compress nerves or blood vessels. 
Zdravilo EVARREST se ne sme uporabljati v zaprtih predelih (npr. znotraj, v okolici ali zraven odprtin ali prehodov v kosteh ali drugih omejenih predelov okoli kosti), kjer lahko pride do otekanja in posledičnega stiskanja živcev ali krvnih žil.
● EVARREST comes ready to use in sterile packages and must be handled using sterile technique in aseptic conditions. 
● Zdravilo EVARREST je pripravljeno za uporabo, pakirano v sterilni ovojnini in ga je treba uporabljati v skladu s sterilnimi tehnikami v aseptičnih pogojih.
If haemostasis is not reached with one application of EVARREST, re-treatment may be administered. 
Če z eno namestitvijo zdravila EVARREST hemostaza še ni dosežena, lahko zdravljenje ponovite.
It was a prospective, randomised, controlled single-centre study observing the clinical utility of EVARREST against Standard of Care (SoC) in soft tissue bleeding during intra-abdominal, retroperitoneal, pelvic and non-cardiac thoracic surgery. 
To je bila prospektivna, randomizirana, kontrolirana, enocentrična študija, ki je spremljala klinično uporabnost zdravila EVARREST v primerjavi s standardno oskrbo (SoC- Standard of Care) pri krvavitvah iz mehkih tkiv pri intraabdominalnih, retroperitonealnih, medeničnih in nekardialnih torakalnih kirurških posegih.
What EVARREST looks like and contents of the pack 
Izgled zdravila EVARREST in vsebina pakiranja
EVARREST is activated upon contact with blood or other fluid and will stick firmly to the tissue. 
Zdravilo EVARREST se aktivira ob stiku s krvjo ali drugo tekočino in se tesno sprime s tkivom.
Apply in a single layer; ensure that the edges overlap (by approximately 1 to 2 cm) with the existing EVARREST sealant matrix. 
Nanesite jih v enem sloju; pazite, da se robovi prekrivajo (približno 1 do 2 cm) z obstoječim matriksom EVARREST.
The product is activated upon contact with fluid, and adheres and conforms to tissue. 
Matriks se aktivira ob stiku s tekočino in se prilepi ter prilagodi tkivu.
EVARREST is applied during surgical operations in adult subjects, to stop bleeding and oozing during the operation. 
Zdravilo EVARREST se uporablja pri kirurških posegih na odraslih bolnikih za ustavitev krvavitve in mezenja krvi med posegom.
EVARREST should not be used in place of sutures or other forms of mechanical ligation for the treatment of major arterial bleeding. 
Zdravilo EVARREST se ne sme uporabljati na mestih, kjer so bili za zdravljenje hudih arterijskih krvavitev uporabljeni šivi ali druge mehanske metode podvezovanja.
EVARREST is a combination product made from an absorbable material (Matrix) coated with human fibrinogen and human thrombin. 
Zdravilo EVARREST je kombinirano zdravilo iz absorbilnega materiala (matriksa), obloženega s humanim fibrinogenom in humanim trombinom.
● Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. 
● Preobčutljivost na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju
QUALITATIVE AND QUANTITATIVE COMPOSITION Component 1: 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Sestavina 1: humani fibrinogen
If you experience an allergic reaction you might have one or more of the following symptoms: swelling under the skin (angioedema), skin rash, hives or wheals (nettle-rash), tightness of the chest, chills, flushing, headache, low blood pressure, lethargy, nausea, restlessness, increased heart rate, tingling, vomiting, or wheezing. 
Če doživite alergijsko reakcijo, se lahko pri vas pojavi eden ali več naslednjih simptomov: podkožna oteklina (angioedem), kožni izpuščaj, urtika (koprivnica), tiščanje v prsih, mrzlica, pordevanje, glavobol, nizek krvni tlak, letargija, slabost, nemir, pospešen srčni utrip, mravljinčenje, bruhanje ali težko dihanje (sopihanje).
Antibodies against components of fibrin sealant/haemostatic products may occur rarely. 
Redko se lahko pojavijo protitelesa na sestavine fibrinskega lepila ali hemostatika.
Once the foil sachet is opened, EVARREST can remain in the sterile field to be available for use throughout the procedure. 
Ko je vrečka iz folije odprta, lahko zdravilo EVARREST ostane na voljo za uporabo na sterilnem mestu ves čas operativnega postopka.
Telefax: +972-3-5316590 
Telefaks: +972-3-5316590
● EVARREST must not be used in the presence of active infection or in contaminated areas of the body because infection may occur. 
● Zdravila EVARREST se ne sme uporabljati v prisotnosti aktivnih okužb ali na kontaminiranih predelih, kjer se lahko pojavi okužba.
A prospective randomised controlled clinical study was conducted enrolling 156 subjects (76 EVARREST, 80 haemostatic fleece) demonstrating the safety and haemostatic effectiveness of EVARREST as an adjunct to controlling bleeding during cardiovascular surgery. 
Izvedena je bila prospektivna, randomizirana, kontrolirana klinična študija, v katero je bilo vključenih 156 oseb (76 oseb, zdravljenih z zdravilom EVARREST, in 80 oseb, zdravljenih s hemostatikom na kolagenskem nosilcu), v kateri so dokazali varnost in hemostatsko učinkovitost zdravila EVARREST kot dopolnilnega zdravila pri nadzoru krvavitve med kardiovaskularnim kirurškim posegom.
The use of more than four 10.2 cm x 10.2 cm units or eight 5.1 cm x 10.2 cm units, or the use in patients that have been previously exposed to EVARREST, has not been studied. 
Uporaba več kot štirih enot zdravila velikosti 10,2 cm × 10,2 cm, več kot štirih enot zdravila velikosti 5,1 cm x 10,2 cm ali uporaba pri bolnikih, ki so že bili zdravljeni z zdravilom EVARREST, še ni bila preučevana.
Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection, and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. 
Pri zdravilih, pripravljenih iz človeške krvi in plazme, so potrebni standardni ukrepi za preprečevanje okužb, in sicer izbira darovalcev krvi in plazme, pregledovanje posameznih darovanih količin in zbirov plazme na označevalce okužb, vključitev korakov učinkovite obdelave krvi in plazme, ki lahko viruse inaktivirajo ali odstranijo.
Remove excess blood or fluid from the site of application if required to improve visibility. 
Z mesta, kamor boste namestili zdravilo, odstranite odvečno kri ali tekočino, če je to potrebno za izboljšanje vidljivosti.
UNIQUE IDENTIFIER-2DBARCODE 2D barcode carrying the unique identifier included. 
EDINSTVENA OZNAKA - DVODIMENZIONALNA ČRTNA KODA Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
Remove the white sterile tray from the pouch and place onto the sterile field. 
Beli sterilni pladenj odstranite iz vrečke in ga položite na sterilno mesto.
5b) To ensure haemostasis, immediately apply manual compression over the entire surface of EVARREST (including the area of overlap) sufficient to stem all bleeding. 
5b) Za zagotavljanje hemostaze z roko nemudoma pritisnite po celotni površini zdravila EVARREST (vključno s področjem prekrivanja) z zadostno silo, da v celoti zaustavite krvavitev.
Parvovirus B19 infection may be serious for pregnant women (foetal infection) and for individuals with immunodeficiency or abnormal erythropoiesis (e.g., haemolytic anaemia). 
Okužba s parvovirusom B19 lahko resno ogroža nosečnice (okužba ploda) in posameznike z imunsko pomanjkljivostjo ali posameznike z nenormalno eritropoezo (npr. hemolitično anemijo).
The amount of EVARREST that will be applied depends on the surface area and location of the bleeding site to be treated during the operation. 
Velikost uporabljenega zdravila EVARREST je odvisna od površine in lokacije krvavečega mesta, ki ga je treba oskrbeti med operacijo.
● EVARREST must not be used to treat severe bleeding from large defects in large arteries or veins where the injured vascular wall requires repair with maintenance of vessel patency and which would result in persistent exposure of EVARREST to blood flow and/or pressure during healing and absorption of the product. 
● Zdravila EVARREST se ne sme uporabljati za zaustavitev hudih krvavitev iz velikih arterij ali ven, kjer poškodba žilnih sten zahteva poseg z ohranjanjeno prehodnostjo žil in bi bilo zdravilo EVARREST med celjenjem in absorpcijo nenehno izpostavljeno krvnemu pretoku in pritisku.
EVARREST is a white-to-yellow bio-absorbable combination product made from a flexible composite Matrix, coated with Human Fibrinogen and Human Thrombin. 
Zdravilo EVARREST je belo do rumeno biološko absorbilno kombinirano zdravilo, ki je izdelano iz fleksibilnega kompozitnega matriksa, obloženega s humanim fibrinogenom in humanim trombinom.
Clinical studies demonstrating haemostasis in mild or moderate soft tissue bleeding were conducted in a total of 141 subjects (111 treated with EVARREST and 30 with control) undergoing abdominal, retroperitoneal, pelvic, and (non-cardiac) thoracic surgery. 
V kliničnih študijah so dokazali hemostazo pri blagih do zmernih krvavitvah mehkega tkiva pri skupno 141 osebah (111 oseb je bilo zdravljenih z matriksom EVARREST, 30 oseb pa je prejemalo kontrolno zdravljenje) med abdominalnimi in retroperitonealnimi operacijami ter operacijami medenice in prsnega koša (brez operacij srca).
Other medicines and EVARREST 
Druga zdravila in zdravilo EVARREST
Human Fibrinogen and Human Thrombin: 
humani fibrinogen in humani trombin:
Multiple bleeding sites may be treated simultaneously. 
Hkrati lahko zdravite več krvavečih mest na telesu.
Anti-thrombin antibodies 
Protitelesa proti trombinu
NAME OF THE MARKETING AUTHORISATION HOLDER Omrix Biopharmaceuticals N.V. 
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Omrix Biopharmaceuticals NV
Talk to your surgeon before you are treated with EVARREST. 
Pred zdravljenjem z zdravilom EVARREST se posvetujte s kirurgom.
The size of EVARREST should be limited to what is necessary to stop bleeding. 
Velikost matriksa EVARREST mora biti omejena na velikost, ki je potrebna za ustavitev krvavitve.
Fibrinogen is a protein extracted from the blood that forms a fibrin clot when acted upon by the enzyme thrombin. 
Fibrinogen je beljakovina, ki jo pridobijo iz krvi in tvori krvne strdke v prisotnosti encima trombina.
EVARREST comes ready to use in sterile packages and must be handled using sterile technique in aseptic conditions. 
Zdravilo EVARREST je pripravljeno za uporabo, pakirano v sterilni ovojnini in je treba z njim ravnati s sterilnimi metodami v aseptičnih pogojih.
The size of EVARREST should be limited to what is necessary for haemostasis. 
Velikost matriksa EVARREST mora biti omejena na velikost, ki je potrebna za hemostazo.
If bleeding still occurs, the EVARREST sealant matrix can be removed, and a new one can be applied. 
Če krvavitev ne preneha, se lahko matriks EVARREST odstrani in namesti novega.
Application of EVARREST 
Uporaba zdravila EVARREST
6.6 Special precautions for disposal and other handling The instructions for use are also described in the in the healthcare professional's package leaflet part. 
Navodila za uporabo so opisana tudi v razdelku z informacijami za zdravstvene delavce v Navodilih za uporabo.
The non-active side has an embossed wave pattern. 
Stran brez zdravilne učinkovine ima izbočen valovit vzorec.
Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infectious agents cannot be totally excluded. 
Vendar kljub temu pri uporabi zdravil, pripravljenih iz človeške krvi ali plazme, ni mogoče povsem izključiti možnosti prenosa okužb.
If you get any side effects, talk to your doctor or surgeon. 
Če opazite kateregii koli izmed neželenih učinkov, se posvetujte z zdravnikom ali kirurgom.
Signs of such reactions include hives, rash, tightness of the chest, wheezing, drop in blood pressure, and anaphylaxis (a severe reaction with a rapid onset). 
Znaki tovrstnih reakcij so koprivnica, izpuščaj, tiščanje v prsih, težko dihanje (sopihanje), hipotenzija in anafilaksa (hitro nastala huda reakcija).
Parvovirus B19 infection may be serious for pregnant women (foetal infection) and for individuals whose immune system is depressed or who have some types of anaemia (e.g., sickle cell disease or haemolytic anaemia). 
Okužba s parvovirusom B19 lahko resno ogroža nosečnice (okužba ploda) in posameznike z imunsko pomanjkljivostjo ali posameznike z anemijio (npr. anemijo srpastih celic ali hemolitično anemijo).
The fibrin clot becomes embedded in the Matrix which enables EVARREST to stick firmly to the surrounding tissue. 
Nastali fibrinski strdek se vdela v matriks, zaradi česar se zdravilo EVARREST trdno oprime okoliškega tkiva.
The total amount of EVARREST left in the body after the operation should not exceed the size of two 10.2 cm x 10.2 cm sealant matrices or four 5.1 cm x 10.2 cm sealant matrices. 
Skupna količina zdravila EVARREST, ki po operaciji ostane v telesu, naj ne preseže velikosti dveh matriksov z lepilom za tkiva v velikosti 10,2 cm x 10,2 cm ali štirih matriksov z lepilom za tkiva v velikosti 5,1 cm x 10,2 cm.
● Hold the tray securely in the palm of the hand, ensuring that the side with the holes is facing upwards, and use the tabs on the side of the tray to remove the top of the tray with the other hand. 
● Pladenj trdno držite z roko tako, da je stran z luknjicami obrnjena navzgor, s pomočjo jezičkov ob straneh pladnja pa z drugo roko odstranite zgornji del pladnja.
Blood clots, including those clots that may travel in blood vessels to other parts of the body, particularly the lungs (pulmonary embolus) may occur after any major surgery. 
Po vsakem večjem kirurškem posegu lahko nastanejo krvni strdki, vključno s strdki, ki lahko po krvnih žilah potujejo v druge dele telesa, še posebej pljuča (pljučni embolus).
EVARREST contains up to 3.0 mmol (68.8 mg) sodium per sealant matrix. 
Zdravilo EVARREST vsebuje do 3,0 mmol (68,8 mg) natrija na matriks.
EVARREST contains sodium 
Zdravilo EVARREST vsebuje natrij
This medicine contains up to 3.0 mmol (68.8 mg) sodium in each EVARREST sealant matrix. 
To zdravilo vsebuje do 3,0 mmol (68,8 mg) natrija v posameznem matriksu EVARREST.
Hold the tray securely in the palm of the hand, ensuring that the side with the holes is facing upwards, and use the tabs on the side of the tray to remove the top of the tray with the other hand. 
Pladenj trdno držite z roko tako, da je stran z luknjicami obrnjena navzgor, s pomočjo jezičkov ob straneh pladnja pa z drugo roko odstranite zgornji del pladnja.
● To open the product, remove the foil sachet from the carton, carefully peel open the foil sachet avoiding contact with the inside of the foil or the white sterile tray containing EVARREST. 
● Zdravilo odprite tako, da iz škatle vzamete vrečko iz folije, jo previdno odprete s potegom, pri tem pa preprečite stik z notranjostjo folije ali belim sterilnim pladnjem, na katerem je zdravilo EVARREST.
● Keep EVARREST dry after opening. 
● Ko zdravilo EVARREST odprete, počakajte, da se posuši.
When the dry powder coating of EVARREST is wetted, the thrombin acts on the fibrinogen to rapidly form a clot. 
Ko se suha prahasta obloga zdravila EVARREST omoči, začneta trombin in fibrinogen nemudoma koagulirati.
The measures taken in the manufacture of fibrinogen and thrombin are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, and for the non-enveloped virus, hepatitis A. The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19. 
Ukrepi, uvedeni v proizvodnji fibrinogena in trombina, so učinkoviti za viruse z ovojnico, kot so virus humane imunske pomanjkljivosti (HIV), virus hepatitisa B in virus hepatitisa C ter za virus hepatitisa A brez ovojnice.
Non-clinical data on the Matrix component reveal no special hazard for humans based on studies of cytotoxicity, sensitization, intracutaneous reactivity, acute systemic toxicity, material-mediated pyrogenicity, subchronic toxicity, genotoxicity, implantation, and hemocompatibility. 
Predklinični podatki o sestavini matriksa na osnovi študij citotoksičnosti, preobčutljivosti, intrakutane reaktivnosti, akutne sistemske toksičnosti, z materialom povzročene pirogenosti, subkronične toksičnosti, genotoksičnosti, vsaditve in hemokompatibilnosti ne kažejo posebnega tveganja za človeka.
Unintentional fluid intake into the airway (aspiration), build up of excess fluid in the cavity surrounding the lungs; the frequency was uncommon (may affect up to 1 in 100 people). 
Nenamerni vdor tekočine v dihalne poti (aspiracija), kopičenje odvečne tekočine v votlini, ki obdaja pljuča; pogostnost je bila občasno (lahko se pojavi pri največ 1 od 100 bolnikov).
Three subjects out of 145 (~2%) in a clinical trial group treated with EVARREST showed an increase in the titre of anti-thrombin antibodies after treatment. 
Pri treh osebah od 145 (~2 %) oseb v skupini v kliničnem preskušanju, zdravljeni z zdravilom EVARREST, so po zdravljenju odkrili zvišanje titra protiteles proti trombinu.
● The lower portion of the tray contains EVARREST with the active side facing downwards. 
● Na spodnjem delu pladnja je zdravilo EVARREST, pri čemer je stran z učinkovino usmerjena navzdol.
The incidence of thromboembolic events, the incidence of post-operative bleeding events specifically related to the target bleeding site and the incidence of increased blood fibrinogen levels were assessed and recorded up to the 30 days follow-up period. 
V obdobju spremljanja do 30 dni so ocenili in evidentirali pojavnost trombemboličnih dogodkov, pojavnost dogodkov pooperativnih krvavitev, specifično povezanih s ciljnim mestom krvavitve, in pojavnost zvišanih ravni fibrinogena v krvi.
- surgery to the brain or spinal cord - controlling bleeding in the stomach or intestines by applying the product through an endoscope 
- operacija možganov ali hrbtenjače, - obvladovanje krvavitve v trebušni votlini in črevesju z endoskopsko vstavitvijo zdravila (skozi cev), - tesnjenje pri kirurških posegih v črevesju.
EVARREST must not be used after the expiry date which is stated on the foil sachet as well as the carton after EXP. 
Zdravila EVARREST ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
Three subjects out of 145 (~2%) in the group treated with EVARREST showed an increase in the titre of anti-thrombin antibodies after treatment. 
Pri treh osebah od 145 (~2 %) oseb v skupini, zdravljeni z zdravilom EVARREST, so po zdravljenju odkrili zvišanje titra protiteles proti trombinu.
To open the product, remove the foil sachet from the carton, carefully peel open the foil sachet avoiding contact with the inside of the foil or the white sterile tray containing EVARREST. 
Zdravilo odprite tako, da iz škatle vzamete vrečko iz folije, jo previdno odprete s potegom, pri tem pa preprečite stik z notranjostjo folije ali belim sterilnim pladnjem, na katerem je zdravilo EVARREST.
● If bleeding is due to insufficient coverage of the bleeding area, additional EVARREST sealant matrices may be applied. 
● Če je krvavitev še prisotna, ker krvaveči predel ni dovolj prekrit, lahko uporabite dodatne matrikse EVARREST.
It is strongly recommended that every time EVARREST is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product. 
Za vodenje evidence o uporabljenih serijah je zelo priporočljivo, da se pri vsaki uporabi zdravila EVARREST zabeležita ime in številka serije zdravila, kar omogoča povezavo bolnika s serijo zdravila.
One (1/75) adverse reaction of deep vein thrombosis was reported in the EVARREST group. 
V skupini z zdravilom EVARREST so poročali o enem (1/75) primeru neželenega učinka globoke venske tromboze.